Results 301 to 310 of about 14,184,553 (374)
Some of the next articles are maybe not open access.
Heterogeneity of factor IX in therapeutic factor IX concentrates
Thrombosis Research, 1978Abstract Rabbit antibody to human factor IX was used to investigate the factor IX antigenic content and electrophoretic mobility of commercial products as well as experimental “activated products”. Rocket immunoelectrophoresis of all concentrates showed a 1.2–3 fold increased antigenic content/unit factor IX clotting activity when compared to plasma.
D. Menache, D.L. Aronson
openaire +3 more sources
Thrombosis Research, 1986
Abnormal factor IX was isolated from the plasma of a patient with hemophilia B Kashihara and two patients with hemophilia BM. The F.IX was purified to homogeneity by using monoclonal anti-F.IX-Sephrose, heparin-Sepharose and DEAE-Sephadex A-50 affinity chromatography successively.
Kanji Ogata +7 more
openaire +3 more sources
Abnormal factor IX was isolated from the plasma of a patient with hemophilia B Kashihara and two patients with hemophilia BM. The F.IX was purified to homogeneity by using monoclonal anti-F.IX-Sephrose, heparin-Sepharose and DEAE-Sephadex A-50 affinity chromatography successively.
Kanji Ogata +7 more
openaire +3 more sources
Thrombosis and Haemostasis, 1997
Despite the introduction of recombinant preparations of factor VIII and recombinant factor VII and VIIa, patients with other forms of hemophilia, especially hemophilia B, have remained at increased risk for blood borne viruses because of a lack of clinically utilizable preparations of recombinant factor IX.
Gilbert C. White +2 more
openaire +3 more sources
Despite the introduction of recombinant preparations of factor VIII and recombinant factor VII and VIIa, patients with other forms of hemophilia, especially hemophilia B, have remained at increased risk for blood borne viruses because of a lack of clinically utilizable preparations of recombinant factor IX.
Gilbert C. White +2 more
openaire +3 more sources
Standardization of Factor IX: Standards for "Purified" Factor IX Concentrates
Thrombosis and Haemostasis, 1991SummaryAn international collaborative study was carried out to determine the suitability of the current WHO II-IX-X concentrate standard, 84/681, for assigning potency to the more highly purified factor IX concentrates. Three Coagulation Factor IX (Human) preparations and one Factor IX Complex preparation were assayed by the one stage method against ...
S C Rastogi, W A Fricke, M A Lamb
openaire +3 more sources
Immune Reactive Factor IX in Acquired Factor IX Deficiency [PDF]
Thrombosis and Haemostasis, 1972 SummaryFactor IX-antibody-neutralizing material has been estimated in plasmas of patients with acquired factor IX deficiency. In patients with liver cirrhosis and patients who had been treated with L-Asparaginase the plasma neutralized an amount of antibody expected from the biological activity. In patients treated with phenprocoumon and in one patient
openaire +2 more sources
Monoclonal antibodies to factor IX: Characterization and use in immunoassays for factor IX
Thrombosis Research, 1984Monoclonal antibodies to factor IX have been characterized for potential use in purification of factor IX and for analysis of factor IX abnormalities seen in hemophilia B and other conditions. The properties of six monoclonal antibodies to factor IX are summarized in this report.
Kenichi Ono, Kenneth J. Smith
openaire +3 more sources
Suppression of Factor IX Antibody in Hemophilia B by Factor IX and Cyclophosphamide
Annals of Internal Medicine, 1973Abstract Two patients with severe hemophilia B complicated by inhibitors of factor IX (equivalent to 0.6 and 4 to 12 units per millilitre plasma, respectively) are described.
Inga Marie Nilsson, G Björlin, U Hedner
openaire +3 more sources
The isolation of prothrombin, factor IX and factor X from human factor IX concentrates
Thrombosis Research, 1984A relatively simple and reproducible procedure is described for the isolation of functionally and electrophoretically homogeneous prothrombin, factor IX and factor X from clinical Factor IX Concentrates. The procedure involves ammonium sulphate fractionation; then chromatography on DEAE-Sephadex A50, dextran sulphate-Sepharose and heparin-Sepharose ...
Frederick A. Ofosu +2 more
openaire +2 more sources
Scandinavian Journal of Haematology, 1977
Fractionation technology has made Factor IX concentrates available. In addition to a very high incidence of hepatitis, thrombosis is being recognized as a consequence of their use. Contradictory reports exist in the literature as to the incidence of thrombotic events.
openaire +3 more sources
Fractionation technology has made Factor IX concentrates available. In addition to a very high incidence of hepatitis, thrombosis is being recognized as a consequence of their use. Contradictory reports exist in the literature as to the incidence of thrombotic events.
openaire +3 more sources
Clinical use of factor VIII and factor IX concentrates.
Blood transfusion = Trasfusione del sangue, 2013Factor VIII (FVIII) and factor IX (FIX) are the cofactor and the pro-enzyme, respectively, acting in the tenase complex, a key mechanism of physiological haemostasis in which a phospholipide-dependent reaction produces the activation of factor X1 ...
M. Morfini +3 more
semanticscholar +1 more source